Prestige Biologics Co. Ltd. (334970) Fair Value & Analysis

Healthcare · KR · Market cap 138B KRW

Below-average quality, and screening another 45% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (1,467 KRW). The favourable scenario is already priced in.
• Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (733.39 KRW to 1,467 KRW) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 1,728 KRW – 19,250 KRW · fair‑value band 733.39 KRW – 1,467 KRW · the 1,778 KRW price screens above the 982.74 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Prestige Biologics Co. Ltd. (334970) currently trades at 1,778 KRW, while our model-based Fair Value estimate is 982.74 KRW, implying the stock looks roughly 44.7% overvalued today. The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at 2.8B KRW. Net debt stands at 89.9B KRW. Fundamentals as of Aug 13, 2026

Our scenario range runs from 733.39 KRW (bear case) to 1,467 KRW (bull case); at 1,778 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 66% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 12% fair-value upside, at -45%, 334970 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and …

Full company description

Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors. Prestige Biologics Co., Ltd. was formerly known as PrestigeBio Pharmaceuticals and changed its name to Prestige Biologics Co., Ltd. in October 2019. The company was founded in 2015 and is based in Cheongju-si, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2020 – FY2024 · reported fiscal years

Prestige Biologics Co. Ltd. reported revenue of 12.5B KRW in FY2024 versus 0 KRW in FY2020. Reported net income was −27.5B KRW in FY2024.

334970 screens 45% overvalued. Compare with Torrent Pharmaceuticals Limited →

Peer Group

Pharmaceuticals · 25 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.